Hutchmed Limited Stock Performance

HMDCF Stock  USD 3.02  0.00  0.00%   
The company retains a Market Volatility (i.e., Beta) of 0.25, which attests to not very significant fluctuations relative to the market. As returns on the market increase, HUTCHMED (China)'s returns are expected to increase less than the market. However, during the bear market, the loss of holding HUTCHMED (China) is expected to be smaller as well. At this point, HUTCHMED Limited has a negative expected return of -0.29%. Please make sure to check out HUTCHMED (China)'s information ratio, and the relationship between the coefficient of variation and skewness , to decide if HUTCHMED Limited performance from the past will be repeated at some future point.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days HUTCHMED Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's fundamental indicators remain nearly stable which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Begin Period Cash Flow235.6 M
Total Cashflows From Investing Activities-306.3 M
  

HUTCHMED (China) Relative Risk vs. Return Landscape

If you would invest  366.00  in HUTCHMED Limited on November 9, 2025 and sell it today you would lose (64.00) from holding HUTCHMED Limited or give up 17.49% of portfolio value over 90 days. HUTCHMED Limited is currently producing negative expected returns and takes up 1.7416% volatility of returns over 90 trading days. Put another way, 15% of traded pink sheets are less volatile than HUTCHMED, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon HUTCHMED (China) is expected to under-perform the market. In addition to that, the company is 2.13 times more volatile than its market benchmark. It trades about -0.17 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

HUTCHMED (China) Target Price Odds to finish over Current Price

The tendency of HUTCHMED Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 3.02 90 days 3.02 
more than 94.0
Based on a normal probability distribution, the odds of HUTCHMED (China) to move above the current price in 90 days from now is more than 94.0 (This HUTCHMED Limited probability density function shows the probability of HUTCHMED Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon HUTCHMED (China) has a beta of 0.25. This usually indicates as returns on the market go up, HUTCHMED (China) average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding HUTCHMED Limited will be expected to be much smaller as well. Additionally HUTCHMED Limited has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   HUTCHMED (China) Price Density   
       Price  

Predictive Modules for HUTCHMED (China)

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as HUTCHMED Limited. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of HUTCHMED (China)'s price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.263.024.78
Details
Intrinsic
Valuation
LowRealHigh
1.423.184.94
Details
Naive
Forecast
LowNextHigh
1.453.214.96
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.803.404.00
Details

HUTCHMED (China) Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. HUTCHMED (China) is not an exception. The market had few large corrections towards the HUTCHMED (China)'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold HUTCHMED Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of HUTCHMED (China) within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.31
β
Beta against Dow Jones0.25
σ
Overall volatility
0.29
Ir
Information ratio -0.21

HUTCHMED (China) Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of HUTCHMED (China) for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for HUTCHMED Limited can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
HUTCHMED Limited generated a negative expected return over the last 90 days
HUTCHMED Limited has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 356.13 M. Net Loss for the year was (194.65 M) with loss before overhead, payroll, taxes, and interest of (201.19 M).
HUTCHMED Limited has accumulated about 829.71 M in cash with (204.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.98.
Roughly 45.0% of the company shares are held by company insiders

HUTCHMED (China) Fundamentals Growth

HUTCHMED Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of HUTCHMED (China), and HUTCHMED (China) fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HUTCHMED Pink Sheet performance.

About HUTCHMED (China) Performance

By analyzing HUTCHMED (China)'s fundamental ratios, stakeholders can gain valuable insights into HUTCHMED (China)'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HUTCHMED (China) has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HUTCHMED (China) has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
HUTCHMED Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. The company was incorporated in 2000 and is headquartered in Central, Hong Kong. Hutchison China operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 2110 people.

Things to note about HUTCHMED Limited performance evaluation

Checking the ongoing alerts about HUTCHMED (China) for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for HUTCHMED Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
HUTCHMED Limited generated a negative expected return over the last 90 days
HUTCHMED Limited has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 356.13 M. Net Loss for the year was (194.65 M) with loss before overhead, payroll, taxes, and interest of (201.19 M).
HUTCHMED Limited has accumulated about 829.71 M in cash with (204.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.98.
Roughly 45.0% of the company shares are held by company insiders
Evaluating HUTCHMED (China)'s performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate HUTCHMED (China)'s pink sheet performance include:
  • Analyzing HUTCHMED (China)'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HUTCHMED (China)'s stock is overvalued or undervalued compared to its peers.
  • Examining HUTCHMED (China)'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating HUTCHMED (China)'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of HUTCHMED (China)'s management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of HUTCHMED (China)'s pink sheet. These opinions can provide insight into HUTCHMED (China)'s potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating HUTCHMED (China)'s pink sheet performance is not an exact science, and many factors can impact HUTCHMED (China)'s pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for HUTCHMED Pink Sheet analysis

When running HUTCHMED (China)'s price analysis, check to measure HUTCHMED (China)'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HUTCHMED (China) is operating at the current time. Most of HUTCHMED (China)'s value examination focuses on studying past and present price action to predict the probability of HUTCHMED (China)'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HUTCHMED (China)'s price. Additionally, you may evaluate how the addition of HUTCHMED (China) to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Fundamental Analysis
View fundamental data based on most recent published financial statements